Arcturus therapeutics stock

Is Arcturus Therapeutics (ARCT) stock a Buy Right Now? Buy an upgrade from Arcturus Therapeutics (ARCT) - Here's what you need to know. Zacks has upgraded Arcturus Therapeutics (ARCT) to #2 (Buy), reflecting growing optimism about the company's earnings outlook. This could push stocks up in the short term.

What does Arcturus Therapeutics' (ARCT) Rs rating indicate?

IBD's unique RS rating provides technical performance by showing how the stock's performance compares to other major index stocks over the past 52 weeks. Arcturus Therapeutics (ARCT) posted stunning results and revenues for the June 2021 quarter ending.

Who is the CEO of Arcturus Therapeutics?

Joe Payne, CEO of Arcturus Therapeutics, was rated by 9 employees with a 90% approval rating among Arcturus Therapeutics employees, according to Joe Payne. Who are Arcturus Therapeutics' main competitors?

Who buys arctarct stock?

During the last quarter, ARCT shares were bought by several institutional investors, including Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., State Street Corp, Morgan Stanley, Morgan Stanley, Nuveen Asset Management LLC, Rafferty Asset Management LLC and Monashi. investment management".

Should you hold Arcturus Therapeutics (ARCT) stock?

Wall Street analysts agree that investors should own shares in Arcturus Therapeutics. The note states that analysts believe that investors should hold existing positions in ARCT, but not buy additional shares or sell existing shares.

Who owns Arcturus Therapeutics?

Company insiders with shares in Arcturus Therapeutics include Andy Sassin, Joseph E. Payne, Keith K. Kummerfeld, Magda Marche, Pad Chivukula and Ultragenyx Pharmaceutical Inc. Check out Arcturus Therapeutics' institutional property trends.

Where can I buy ARCT shares?

ARCT shares can be purchased through any online brokerage account. Popular online brokers include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare the best brokers here.

Is arcturus therapeutics (arct) stock a buy right now 2020

ARCT currently has the lowest sentiment rating (where it outperforms US stocks). In a price-to-volume ratio, Arcturus Therapeutics Holdings Inc., this ratio is higher than the company's stock as a whole.

Is Arcturus Therapeutics Holdings Inc (ARCT) a good stock to buy?

They use technical analysis to predict the future value of a wide variety of stocks, such as Arcturus Therapeutics Holdings Inc (ARCT). If you are looking for high performing stocks, Arcturus Therapeutics Holdings Inc. be a profitable investment option.

How has Arcturus Therapeutics' stock performed during covid-19?

Arcturus Therapeutics traded at $111 on March 11, 2020, when COVID19 (coronavirus) reached pandemic status, according to the World Health Organization. Since then, ARCT shares have risen and are now trading at USD. See which stocks have been most affected by COVID19. What was the target price for ARCT?

What does a hold rating mean for Arcturus Therapeutics (ARCT)?

The note states that analysts believe that investors should hold existing positions in ARCT, but not buy additional shares or sell existing shares. Check out Arcturus Therapeutics' analyst reviews or check out the top-rated stocks. What are Arcturus Therapeutics MarketBeat's Preferred Stock?

What does Arcturus Therapeutics do?

Arcturus Therapeutics Holdings Inc., an RNA pharmaceutical company, specializes in the treatment of liver and respiratory diseases.

Is arcturus therapeutics (arct) stock a buy right now 2021

The price of Arcturus Therapeutics Holdings Inc. rose from dollar to dollar on the last trading day (Thursday, September 16, 2021). During the day, the stock price fluctuated from a daily low to a dollar with a daily high in dollars. They fluctuated up and down during this period and there were losses in the last 2 weeks.

Who sold ARCT stock in the last quarter?

During the last quarter, ARCT shares were sold by several institutional investors, including ARK Investment Management LLC, Federated Hermes Inc., Millennium Management LLC, Goldman Sachs Group Inc., Renaissance Technologies LLC, Price T Rowe Associates Inc., MD, Group One trade.

Is arcturus therapeutics (arct) stock a buy right now cheap

When it comes to market price volatility, ARCT is more volatile than the stocks it tracks. Stocks with the same financial performance, market capitalization and price volatility as Arcturus Therapeutics Holdings Inc include XENE, PTGX, SGMO, TTNP and ENTA.

What is Arcturus Therapeutics' price targets for next year?

On average, they expect Arcturus Therapeutics stock to hit the US dollar next year. This indicates a possible increase in the current value of the shares. View price targets from Arcturus Therapeutics analysts or view top-rated Wall Street analysts.

Who is the ceo of arcturus therapeutics news

Joseph E. Payne, MS Joseph E. Payne is president and CEO of Arcturus Therapeutics. He has been a member of the board of directors of Arcturus since March 2013. He has exceptional experience introducing novel clinical therapies, including RNA-targeted drugs with lipid-mediated delivery technologies.

Who is the ceo of arcturus therapeutics stock

Joseph E. Payne, President and CEO and Chairman of the Board Joseph E. Payne is President and CEO of Arcturus Therapeutics. He has been a member of the board of directors of Arcturus since March 2013.

Who is the ceo of arcturus therapeutics 2020

Joseph Payne, CEO of Arcturus Therapeutics (ARCT), in a transcript of the Q1 2020 conference call on May 11, 2020, 4:01 a.m. ET, Arcturus Therapeutics Holdings Inc.

Who is the ceo of arcturus therapeutics products

Padmanabh Chivukula, CSO and COOPad Chivukula, is the Chief Scientific Officer and COO of Arcturus Therapeutics.

Who is the CEO of Arcturus?

Joseph E. Payne, President and CEO and Chairman of the Board Joseph E. Payne is Chairman and CEO of Arcturus Therapeutics Ltd.

What is Arcturus Therapeutics?

Arcturus Therapeutics was founded in 2013 by Joseph Payne and Dr. J. Pad Chivukula and is based in San Diego, California, USA. The company's flagship technology platform is a patented lipid nanoparticle delivery system that can deliver therapeutic RNA or DNA to target cells in a patient's body.

What is Arcturus' technology platform?

Arcturus Therapeutics' main technology platform for RNA therapy is called LUNAR, a novel lipid-mediated delivery system. LUNAR is a multi-component drug delivery system that allows scientists to target specific cells in the body and deliver an RNA payload into the cell.

What is Arcturus LUNAR?

Arcturus has developed a new, efficient and safe RNA-based therapeutic platform called LUNAR, a patented nucleic acid-based drug delivery system for drugs including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA. , antisense oligonucleotides (ASO) and microRNA.

Who is Arcturus Therapeutics Holdings?

Arcturus Therapeutics Holdings Inc. Founded in 2013, based in San Diego, California™ (Nasdaq: ARCT) specializes in mRNA and (iii) mRNA technology for substances and expertise in drug manufacturing.

What types of RNA Therapeutics does Arcturus offer?

Arcturus' versatile RNA therapy platforms can be applied to a variety of nucleic acid-based drugs, including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing techniques.

Does Arcturus Therapeutics pay for unsolicited resumes sent from recruiters?

Unsolicited resumes submitted to Arcturus Therapeutics by recruiters do not constitute a relationship between the recruiter and Arcturus Therapeutics and Arcturus Therapeutics will not charge a recruiting fee for such resumes.

What is Arcturus' patent portfolio?

Arcturus technologies are protected by a broad patent portfolio (230 patents and patent applications issued in Europe, Japan, China and other countries).

Why is Arcturus Therapeutics Holdings Inc (ARCT) investing in Vietnam?

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) partnered with Vinbiocare to open a manufacturing facility in Vietnam to produce research COVID19 vaccines for sale and use in Vietnam. Under the terms of the agreement, Vinbiocare will build a factory in Vietnam in consultation with Arcturus.

What does estestimated return mean for Arcturus Therapeutics?

Estimated earnings are the expected annual returns you can expect after buying and owning stock in a company over a standard 5-year period based on projected earnings per share growth.. Arcturus Therapeutics Relative Strength Index improved from 77 to 85 on Wednesday.

Is Arcturus Therapeutics' covid-154 vaccine candidate approved in Vietnam?

The Vietnamese Ministry of Health approved a Clinical Trial Application (CTA) from Arcturus Therapeutics Holdings Incs (NASDAQ: ARCT) to promote the vaccine candidate COVID19 ARCT154 against related variants.